{
    "nctId": "NCT04290793",
    "briefTitle": "Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer",
    "officialTitle": "Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER2+Breast Cancer: a Multicenter, Randomized, Open-label, Parallel-Group Controlled Trial",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 280,
    "primaryOutcomeMeasure": "Pathological Complete Response rate(pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female breast cancer patients at the age of \\>= 18 years and \\<= 65 years who received first treatment\uff1b\n2. Pathologically confirmed HER2-positive invasive breast cancer\uff08which is defined as the immunohistochemistry score of \\> 10% immunoreactive cells being 3+ or in situ hybridization results showing HER2 gene amplification\uff09\uff0cregardless of hormone receptor status (ER and PR)\uff1b\n3. According to the 2019 CSCO BC guidelines: When HER-2 positive is used as the standard for preoperative neoadjuvant therapy for breast cancer, the tumor is larger than 2 cm\uff1b\n4. The Eastern Tumor Collaborative Group (ECOG) has a physical status score of \u22641\uff1b\n5. The functional level of the main organs must meet the following requirements \uff1a 1) blood routine test: hemoglobin (Hb) \u2265 90g/L;Neutrophils (ANC) \u2265 1.5 \u00d7 10\\^9/L; platelet count (PLT) \u2265 90 \u00d7 10\\^9/L; 2) Blood biochemistry: Total bilirubin (TBIL) \u2264 1.5 upper limit of normal value (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 1.5 \u00d7 ULN; alkaline phosphatase \u2264 2.5 \u00d7 ULN; Urea nitrogen (BUN) and creatinine (Cr) \u2264 1.5 \u00d7 ULN; 3) Heart color ultrasound: Left ventricular ejection fraction (LVEF) \u2265 55%;\n6. Women of childbearing age, tested negative for serum pregnancy test 7 days before randomization\uff0cand willing to use appropriate methods during the trial and within 8 weeks after the last administration of the test drug;\n7. A volunteer to participate in the study; provision of written informed consent; good compliance and willing to cooperate during the follow-up.\n\nExclusion Criteria:\n\n1. Known history of hypersensitivity to pyrotinib or any of it components;\n2. Patients have previously received antitumor treatment or radiation therapy for any malignant tumor (except for cervical carcinoma in situ and basal cell carcinoma that have been cured);\n3. Patients underwent major breast cancer-free surgery within 4 weeks and have not fully recovered;\n4. Subjects that are unable to swallow tablets,intestinal obstruction or dysfunction of gastrointestinal absorption;\n5. Patients with severe heart disease or discomfort who cannot be treated;\n6. The patient suffers from mental illness or psychotropic substance abuse and cannot cooperate;\n7. Pregnant or lactating women;\n8. Less than 4 weeks from the last clinical trial;\n9. Patients participating in other clinical trials at the same time\n10. The researchers think inappropriate.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}